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Structured abstract 
 
Background: Use of antipsychotics to treat behavioural symptoms of dementia has been associated 
with increased risks of mortality and stroke. Little is known about individual patient characteristics 
that might be associated with bad or good outcomes. 
Aims: We examined the risperidone clinical trial data to look for individual patient characteristics 
associated with these adverse outcomes. 
Method:  Data from all double-blind, RCTs of risperidone in dementia patients (1009 risperidone, 712 
placebo) were included. Associations between characteristics and outcome were analysed based on 
crude incidences, exposure-adjusted incidence rates, and by time-to-event analyses using Cox 
proportional hazards regression. Interactions between treatment (risperidone or placebo) and 
characteristic were analysed with a Cox proportional hazards regression model with main effects for 
treatment and characteristic in addition to the interaction term.   
Results: Baseline complications of depression (treatment by risk factor interaction on CVAE hazard 
ratio [HR]: p = 0.025) and delusions (p = 0.043) were associated with a lower relative risk of CVAE in 
risperidone treated patients (HR=1.47 and 0.54, respectively) compared to not having the 
complication (HR=5.88 and 4.16). For mortality, the only significant baseline predictor in patients 
treated with risperidone was depression, which was associated with a lower relative risk (p<0.001). 
The relative risk of mortality was increased in risperidone patients treated with anti-inflammatory 
medications (p=0.021). 
Conclusions: Only anti-inflammatory medications increased mortality risk with risperidone. The 
reduced risk of CVAE in patients with co-morbid depression and delusions, and of mortality with 
depression may have clinical implications when weighing the benefits and risks of treatment with 
risperidone in patients with dementia.  
Declaration of interest: KK, DC and DH are employees of Janssen Research and Development and are 
owners of Johnson and Johnson stock. JB is an employee of Johnson and Johnson and is an owner of 
Johnson and Johnson stock. RH has received medication from Pfizer-Eisai and Lundbeck for an 
independent clinical trial on which he was Chief Investigator. SGC reports no financial relationships 
with commercial interests. 
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Introduction 
Risperidone is licenced by the European Medicines Agency for the short-term (up to 6 weeks) 
treatment of persistent aggression in patients with moderate to severe Alzheimer's dementia 
unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others 
(1). Meta-analysis of primary efficacy and safety data from four of the risperidone trials has been 
published (2), together with an analysis of mortality in six studies (3). As physicians who are frequently 
faced by decisions about treatment in this situation, RH and SGC approached Janssen with two 
questions. First, given the known risks of risperidone treatment in this population (3-7), were there 
baseline characteristics of individual patients within the clinical trials database that could be used to 
identify those at higher (or lower) risk of death or CVAE associated with risperidone treatment? 
Second, once treatment had been initiated, which treatment-emergent events were associated with 
risk of subsequent death or CVAE in patients treated with risperidone? We conducted a meta-analysis 
of all Janssen’s double-blind randomized controlled trials of risperidone in dementia to address these 
questions, with a focus on identifying patient characteristics and treatment emergent events that 
would result in differential risk of stroke and death to risperidone and placebo.   
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Methods 
Study Selection 
Data from all 6 randomized, double-blind, placebo-controlled studies of risperidone in elderly patients 
with dementia conducted by Janssen were included in this analysis. The primary results of four of the 
studies (USA-63 (NCT00253123) (8), INT-24 (NCT00249145) (9), AUS-5 (NCT00249158) (10), and USA-
232 (NCT00034762) (11)) have been previously published. The current analysis also includes 2 studies 
which were not published due to insufficient numbers of subjects: a pilot study, BEL-14 (N=39), and 
INT-83 (N=18), which was terminated for (non-clinical) business reasons. 
Detailed study design characteristics are available in the primary publications. All included males and 
females aged ≥55 years with Alzheimer’s, vascular, or mixed dementia as classified by the Diagnostic 
and Statistical Manual of Mental Diseases, 4th Edition (DSM-IV) (12). In 4 studies (USA-63, INT-24, AUS-
5, BEL-14), a BEHAVE-AD (13) total score ≥8 and a BEHAVE-AD global rating of ≥1 were inclusion 
criteria. In USA-232 and INT-83, a score of ≥2 on any item of the BEHAVE-AD psychosis subscale was 
an inclusion criterion. Treatment duration was 12 weeks for USA-63, INT-24, and AUS-5; 8 weeks for 
USA-232 and INT-83; and 4 weeks for BEL-14. USA-63 included 3 fixed dose arms of risperidone (0.5, 
1, or 2 mg daily). Flexible dosing was employed in the other studies, with total daily dose ranges of 
0.5-4 mg in INT-24, 0.5-2 mg in AUS-5, 1-4 mg in BEL-14, and 1-1.5 mg in USA-232 and INT-83. For the 
current analysis, all risperidone doses were combined into a single group.  
Variable Definitions 
The following baseline characteristics were examined for an association with CVAE or mortality: age 
(<80 years vs. ≥80 years), sex, race, diagnosis, body mass index (BMI), Mini-Mental State Examination 
(14), BEHAVE-AD delusion-related items, BEHAVE-AD global rating, creatinine clearance , diastolic 
blood pressure, pulse, blood levels of sodium and urea, cardiovascular, neurological, or respiratory 
findings on medical history, and cardiovascular, neurological, or respiratory findings on baseline 
physical examination. Detailed criteria for each baseline characteristic are in the full statistical analysis 
plan available on-line.  
Treatment-emergent events examined for an association with CVAE or mortality included weight 
increase (≥7% increase), weight decrease (≥7% decrease), creatinine clearance decrease (≥10% and 
≥20%), diastolic blood pressure (>90 mmHg), sedation, malnutrition, dehydration, extrapyramidal 
symptoms, pulmonary condition, infection (urinary or pulmonary), and cardiovascular disease adverse 
events. A treatment-emergent event was considered ‘present’ only if the earliest occurrence of the 
event preceded the CVAE or death. In an additional analysis, the treatment-emergent event was 
considered ‘present’ only if the earliest occurrence of the event preceded the CVAE or death by at 
least 7 days. 
Selected categories of concomitant medications, based on the WHO Drug Dictionary Anatomic-
Therapeutic-Chemical (ATC) class, were also examined for their association with CVAE or mortality: 
potentially sedating medications, anti-inflammatory drugs, beta blockers, diuretics, and laxatives. 
Concomitant medication use was defined in the same ways as the presence of a treatment-emergent 
event, based on the earliest start date of the concomitant medication (medications with a missing 
start date were considered to have been present from baseline). 
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Statistical Methods 
For analysis of differences between risperidone and placebo in individual studies, Fisher’s exact test 
was used to compare the crude incidences of CVAE and mortality and Wald’s method was used to 
compare exposure adjusted incidence rates (EAIRs) (15). Analysis based on the combined studies used 
the Cochran-Mantel-Haenszel test for crude incidence and the Mantel-Haenszel-type method of 
Greenland and Robins (16) for EAIRs. 
The association between a CVAE or mortality and a baseline characteristic or treatment-emergent 
event (including concomitant medication use) was analysed by Fisher’s exact test for crude incidence 
and Wald’s method for EAIR. The placebo group only were included in these analyses and the analysis 
was based on the cross-tabulation of the event of interest (CVAE or mortality) versus the characteristic 
(baseline or treatment-emergent). For treatment-emergent events, an additional analysis by Cox 
proportional hazards regression was performed with the treatment-emergent event as a time-varying 
covariate. Analyses of treatment-emergent events were performed for both definitions of being 
present (earliest onset before the CVAE or mortality and earliest onset ≥7 days before the CVAE or 
mortality). In the Cox regression, the treatment-emergent event was considered present from the 
time of its onset, however defined, until the onset of the CVAE or mortality or until study 
discontinuation for subjects who did not have a CVAE or die. In this way, the treatment-emergent 
event is considered to become a subject characteristic at the time of its onset. 
To evaluate how a baseline characteristic or treatment-emergent event modified the difference 
between risperidone and placebo, a Cox regression with factors of treatment group, baseline 
characteristic or treatment-emergent event, and the interaction of treatment and baseline 
characteristic or treatment-emergent event was performed. Treatment-emergent events (including 
concomitant medications) were included as time-varying covariates as described above. The 
significance of the interaction term was based on likelihood ratio statistics comparing the models with 
and without that term. Hazard ratios (HRs) and 95% confidence intervals comparing risperidone and 
placebo were estimated from the full model at both levels of the baseline characteristic or treatment-
emergent event.  
All statistical analyses were performed using SAS Version 9.2 (17). Figures were generated using the R 
lattice package (18). 
Nominal p-values are presented throughout; there was no adjustment for multiplicity.  
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Results 
(1) Overall and comparative incidence of CVAE and mortality in all patients with dementia and 
behavioural symptoms treated with risperidone or placebo 
1009 risperidone- and 712 placebo-treated patients were included in the combined database. 
Demographic features of patients are reported in Table 1.  
There was a statistically significant difference in the crude incidence of all CVAEs across all studies: 
risperidone (49/1009, 4.9%) and placebo (11/712, 1.5%); (p<0.001, Cochran-Mantel-Haenszel test 
stratified by study) (Table 2). Crude incidence of mortality was numerically higher in the risperidone 
(40/1009, 4.0%) than placebo (22/712, 3.1%) group, but the between-group difference was not 
statistically significant (p=0.527, Cochran-Mantel-Haenszel test stratified by study). The risperidone 
group had a statistically significantly higher exposure-adjusted incidence of any CVAE across all studies 
compared to placebo (p<0.001). Exposure-adjusted incidence of mortality was higher in the 
risperidone group compared to the placebo group, but this was not statistically significant (p=0.466). 
(2) Risk Factors in patients with dementia and behavioural symptoms treated with placebo 
Baseline patient characteristics that predicted CVAE or Mortality in patients treated with placebo: 
crude incidence analysis 
Figure 1 summarizes the crude incidence of CVAEs and mortality in placebo patients with and without 
the identified risk factors. Placebo patients with age>80 years (p=0.020) and with baseline depressed 
mood (p=0.047) were at increased risk of CVAE. Analysis of potential baseline risk factors for mortality 
indicated that severe impairment of creatinine clearance (p=0.024) and depressed mood (p=0.023) 
were significantly associated with increased mortality, while male sex (p=0.056) and severe dementia 
(MMSE<9) (p=0.087) failed to reach accepted significance levels.  
Baseline patient characteristics that predicted CVAE or Mortality in patients treated with placebo: 
exposure-adjusted incidence rate (EAIR) 
Analyses based on EAIR differences between placebo patient characteristic groups identified age>80 
years (p=0.004) and BEHAVE global rating less than severe (p=0.045) as significant risk factors for 
CVAE, while cardiovascular medical history (p=0.073) failed to reach accepted significance levels. No 
significant risk factors for mortality were identified, with age>80 (p=0.096), severe impairment of 
creatinine clearance (p=0.093), depressed mood (p=0.074) and male sex (p=0.081) failing to reach 
significance. 
Treatment-emergent adverse event risk factors (TERF) that predicted CVAE or Mortality in patients 
treated with placebo: crude incidence analysis 
No TERFs were significantly associated with CVAE. TERFs associated with increased mortality included 
dehydration (p<0.001), infection (p<0.001) and pulmonary conditions (p=0.012), while cardiovascular 
disease (p=0.058) and sedation (p=0.068) failed to reach accepted significance levels. (See Figure 2).  
Treatment-emergent adverse event risk factors (TERF) that predicted CVAE or Mortality in patients 
treated with placebo: exposure-adjusted incidence rate 
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For EAIR of CVAE by TERF none of the examined risk factors was significantly associated. For EAIR of 
mortality by TERF, dehydration (p=0.042) and infection (p=0.007) emerged as significant, while 
pulmonary conditions (p=0.056) failed to reach significance. 
Cox regression did not identify TERFs significantly associated with CVAE. Risk factors for mortality 
confirmed as statistically significant by Cox regression included cardiovascular TEAE (HR=9.68; 95% CI: 
2.2 to 42.65; p=0.022), creatinine clearance decrease >20% (HR=9.86; 95% CI: 1.98 to 49.07; p=0.024), 
dehydration (HR=31.61; 95% CI: 10.49 to 95.25; p<0.001), infection (HR=5.82; 95% CI: 2.39 to 14.18; 
p<0.001) and pulmonary condition (HR=5.22; 95% CI: 2.07 to 13.12; p=0.001). Weight decrease >7% 
(HR=5.87; 95% CI: 1.22 to 28.26; p=0.065) and sedation (HR=3.05; 95% CI: 1.09 to 8.52; p=0.054) failed 
to reach significance levels. 
Treatment-emergent adverse events risk factors (TERF) that predicted CVAE or Mortality in patients 
treated with placebo: TERF analysis with 7-day offset 
For the crude incidence of CVAE, no TERF was statistically significant. For the crude incidence of 
mortality, significant TERFs identified included dehydration (p=0.013), infection (p=0.004), and 
pulmonary condition (p=0.050), while weight decrease >7% (p=0.081) did not reach statistical 
significance.  
Analyses based on exposure-adjusted incidence rate differences between TEAE groups (results 
available online) did not identify any new risk factors for CVAE compared to analysis of crude incidence 
and only infection (p=0.045) was significantly associated with mortality. Analyses based on the Cox 
regression identified the same risk factors for increased mortality as analysis without the 7-day offset,  
together with an additional risk factor, weight decrease >7% (HR=6.68; 95% CI: 1.4 to 31.88; p=0.050). 
Effects of concomitant medication use on risk of CVAE or mortality in placebo patients 
There was a non-significant trend for anti-inflammatory drugs to be associated with a lower risk of 
death in the EAIR analyses (p=0.081) and for sedating medications to be associated with increased 
mortality based on Cox regression (HR=2.15; 95% CI: 0.86 to 5.4; p=0.094). 
(3) Risk Factors in patients with dementia and behavioural symptoms treated with risperidone 
This analysis investigated which factors conferred a difference in risk between patients treated with 
risperidone relative to those treated with placebo, as evidenced by a significant treatment-by-risk 
factor interaction in the Cox regression between the HR of risperidone and placebo in those with or 
without the risk factor. Results for those baseline characteristics, TERFs, or concomitant medications 
that had a statistically significant treatment-by-factor interaction term are summarized in Table 3A for 
CVAE and Table 3B for mortality. 
Baseline patient characteristics that modified the differential risk for CVAE and mortality in patients 
treated with risperidone compared to placebo 
For CVAE, a significant interaction effect was observed for age>=80 years, positive cardiovascular 
medical history, baseline delusions, and baseline depressed mood. For baseline delusions and 
depressed mood, the risperidone:placebo HR was lower in patients with the complication (1.47, 95% 
CI: 0.59 to 3.65 for delusions; 0.54, 95% CI: 0.12 to 2.40 for depressed mood) compared to patients 
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without the complication (5.88, 95% CI: 2.09 to 16.53 for delusions; 4.16, 95% CI: 1.96 to 8.82 for 
depressed mood). For age>=80 years and cardiovascular medical history, the significant interaction 
was likely the result of no placebo patients without the baseline characteristic having a CVAE. The 
relative risk of CVAE among subjects with age>=80 years or with cardiovascular medical history is 
similar to the relative risk among all patients as shown in Table 2. 
For mortality, a significant interaction effect was observed for baseline depressed mood with more 
deaths in the placebo group (5/54, 9.3%) than in the risperidone group (0/112) among patients with 
baseline depressed mood compared to more deaths in the risperidone group compared to the placebo 
group among patients without depressed mood at baseline (HR=1.52, 95%: 0.86 to 2.70). 
Treatment emergent risk factors that modified the differential risk for CVAE and mortality in 
patients treated with risperidone compared to placebo 
Only creatinine clearance decrease of >20% was associated with a modified hazard ratio for mortality 
(HR if risk factor present undefined as no CVAEs in risperidone group; HR if risk factor not 
present=2.49; 95% CI 1.24 to 5.02; p=0.049). There was only 1 event (in a placebo-treated subject vs. 
no events in the risperidone-treated group) among those with the creatinine clearance decrease. 
There were no TERFs associated with an excess mortality risk in patients treated with risperidone 
when compared with placebo-treated patients.  
Concomitant medication use that modified the differential risk for CVAE and mortality in patients 
treated with risperidone compared to placebo 
There were no concomitant medications whose use was associated with differential CVAE risk in 
patients treated with risperidone compared to placebo. The treatment-by-risk factor interaction term 
was statistically significant for analyses of mortality for anti-inflammatory drug use, with a higher 
risperidone:placebo hazard ratio in patients with use of these drugs (HR if risk factor present=3.42; 
95% CI: 1.00 to 11.76; HR if risk factor not present=0.78; 95% CI: 0.42 to 1.43; p=0.021). The presence 
or absence of the 7-day offset did not change this result.  
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Discussion 
Meta-analyses of clinical trials in elderly patients with dementia indicate that individual antipsychotic 
drugs have different mortality risks, with quetiapine being associated with the lowest, and haloperidol 
being associated with the highest risk of death (6,7,19,20). For a given drug, there is a dose-response 
relationship with mortality (7).  A physician, faced with a patient whose symptoms and behaviour are 
distressing and can place the patient and others at significant danger, needs to evaluate the potential 
benefits on balance with the risks of treatment in an individual case (21). For example, depending on 
the atypical antipsychotic, the number of patients that would need to be treated to observe 
improvement in psychosis and aggression in a single patient ranges from 5 to 14 (5), with quetiapine 
having less convincing evidence for efficacy than risperidone and olanzapine (7,22). There is a 
significant chance that psychosis symptoms will return when treatment is stopped (23). The most 
extreme contrasting risk of treatment is reflected by the number of patients needed to be treated to 
observe a single death, ranging from 27 to 100 (4,7).  
In terms of baseline patient factors associated with increased exposure-adjusted incidence of CVAE in 
placebo-treated patients, we confirmed the previously reported age>80, as well as finding the novel 
BEHAVE global rating less than severe, while no significant risk factors for mortality were identified by 
this method. No treatment-emergent events were associated with increased exposure-adjusted 
incidence of CVAE in placebo-treated patients. Treatment-emergent events associated with increased 
exposure-adjusted incidence of mortality were dehydration, infection, and pulmonary conditions. 
Baseline characteristics that modified the risk of CVAE in patients treated with risperidone compared 
to placebo included age>=80 and cardiovascular disease history. Presence of delusions or depressed 
mood at baseline was associated with a lower risperidone:placebo hazard ratio for CVAE compared to 
not having those complications. Baseline depressed mood was also associated with a reduced 
risperidone:placebo hazard ratio for mortality. None of the investigated treatment emergent risk 
factors modified the differential risk for CVAE and mortality in patients treated with risperidone 
compared to placebo except for creatinine clearance decrease >20%, which was associated with a 
reduced hazard ratio for CVAE. This is hard to explain and may be a consequence of the very small 
number of patients with an observed creatinine clearance decrease prior to a CVAE. There was only 
one CVAE in a placebo-treated patient versus none in the risperidone group among participants with 
the creatinine clearance decrease. We also found that concomitant use of anti-inflammatory drugs 
was associated with a greater risperidone:placebo hazard ratio for mortality compared to no use of 
such drugs. 
Our data show some overlap with the results of the analysis of the integrated olanzapine database 
(24), which identified age>80, concomitant benzodiazepine use, treatment-emergent sedation and 
pulmonary conditions to be associated with an increased risk of mortality, and that age>80 and 
diagnosis of vascular or mixed dementia were associated with an increased risk of CVAE. However, 
this analysis identified risk factors in a combined sample of patients treated with olanzapine or 
placebo. Their results would therefore reflect a combination of background risk factors for CVAE and 
death in a general elderly population (from placebo patients), with specific risk factors for an adverse 
outcome in patients treated with olanzapine. By examining for characteristics that modified risk in 
patients treated with risperidone compared to placebo, rather than simply in the combined trial 
population, we were able to identify patient related factors that could potentially inform a more 
individualised benefit-risk analysis in the initiation of antipsychotic treatment. 
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The association of delusions or depression with reduced CVAE risk and depression with reduced 
mortality in risperidone compared with placebo-treated patients may indicate that specific psychiatric 
symptoms, rather than clusters of behaviours such as agitation, marks patients for whom atypical 
antipsychotic treatment carries less risk. In the Clinical Antipsychotic Trials of Intervention 
Effectiveness-Alzheimer’s Disease (CATIE-AD) study (25), specific symptoms including paranoid ideas 
were more likely to improve with atypical antipsychotic treatment (26). Also, in a meta-analysis of 
placebo-controlled risperidone trials (2), “people are stealing things” or infidelity delusions were more 
likely to respond to treatment than other symptoms. A meta-analysis of atypical trials in dementia, 
however, reported smaller treatment effect sizes for patients selected on the basis of psychosis 
symptoms (27), so the literature is not consistent. Our data add to evidence that delusions may 
represent a target symptom in AD where potential treatment benefits are significant and risks of CVAE 
smaller. This finding will need to be replicated in an independent sample before it can form the basis 
for advice to guide clinicians when making decisions about stratifying risk in this treatment indication. 
However, our data add to an emerging story that the presence of particular individual psychiatric 
symptoms in patients with dementia is associated with both the potential benefits and risks of 
antipsychotic treatment.  
Although anti-inflammatory drugs are associated with increased cardiovascular events and all-cause 
mortality in the general medical population (28), these agents did not increase the risk of stroke or 
death in placebo patients in the trials examined here. The increased relative mortality in risperidone 
patients who also were treated with anti-inflammatory medications represents an easily modifiable 
risk factor in clinical practice.  
A limitation of our findings is that, as in previous investigations of potential risk factors for stroke and 
death in dementia patients treated with an atypical antipsychotic by other authors (24), we did not 
make statistical correction of our results for the effects of multiple comparisons. We would 
acknowledge that some of our findings, with p values in the 0.02 to 0.05 range, might have arisen by 
the effects of chance and the multiple statistical comparisons made in our analyses. We would argue 
that this is unlikely, and that the consistency of the findings with what we understand clinically and 
with each other argues against such a negative explanation.         
Clinicians will continue to consider antipsychotic short term treatment for behavioural and psychiatric 
symptoms in dementia when those symptoms cause significant distress or carry risk of harm to the 
patient or others, and when alternative, non-pharmacological interventions are unavailable or have 
failed (21,39). These symptoms are independently associated with more rapid progression to severe 
dementia and earlier death (30) and their treatment represents a potential opportunity to modify the 
clinical course of dementia. Our analysis has confirmed some of the previously established patient 
factors associated with increased risk of CVAE and mortality during antipsychotic treatment. 
Importantly, we have also reported that the presence of some psychiatric symptoms was associated 
with reduced risk of CVAE and mortality within the population of dementia patients treated with 
risperidone in the pivotal trials.  
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Table 1: Demographics of patients in double-blind placebo-controlled risperidone studies 
 
Characteristic PLACEBO RISPERIDONE HALOPERIDOL Total 
    Parameter (N712) (N1009) (N115) (N1836) 
Age, years  
    N 712 1009 115 1836 
    Mean (SD) 82.2 (7.69) 82.7 (7.24) 81.0 (7.60) 82.4 (7.45) 
    Median 83.0 83.0 82.0 83.0 
    Range 56 - 100 58 – 105 56 – 97 56 - 105 
     
Sex, n (%)  
    N 712 1009 115 1836 
    Female 498 (70) 702 (70) 62 (54) 1262 (69) 
    Male 214 (30) 307 (30) 53 (46) 574 (31) 
     
Race, n (%)  
    N 693 989 115 1797 
    Black 36 (5) 65 (7) 0 101 (6) 
    Caucasian 623 (90) 885 (89) 115 (100) 1623 (90) 
    Hispanic 20 (3) 22 (2) 0 42 (2) 
    Oriental 11 (2) 11 (1) 0 22 (1) 
    Other 3 (<1) 5 (1) 0 8 (<1) 
    Polynesian 0 1 (<1) 0 1 (<1) 
     
Weight, kg  
    N 689 980 108 1777 
    Mean (SD) 60.29 (13.084) 59.74 (13.117) 62.26 (12.334) 60.11 (13.065) 
    Median 59.02 58.11 60.00 59.00 
    Range 33.2 - 112.7 30.0 - 145.4 40.0 - 90.0 30.0 - 145.4 
     
Height, cm  
    N 675 956 96 1727 
    Mean (SD) 160.84 (10.912) 160.54 (10.794) 162.91 (10.183) 160.79 (10.814) 
    Median 160.02 160.02 163.00 160.02 
    Range 115.0 - 196.0 115.0 – 198.1 144.0 - 192.0 115.0 - 198.1 
 
Body Mass Index, kg/m2 
    N 667 943 96 1706 
    Mean (SD) 23.32 (4.650) 23.22 (4.548) 23.57 (4.205) 23.28 (4.568) 
    Median 22.80 22.80 23.35 22.80 
    Range 13.3 - 51.9 11.3 - 54.7 16.1 - 35.8 11.3 - 54.7 
     
Baseline MMSE total score  
    N 699 988 114 1801 
    Mean (SD) 9.0 (6.63) 8.3 (6.63) 8.0 (6.52) 8.5 (6.63) 
    Median 9.0 8.0 8.0 8.0 
    Range 0 - 23 0 – 24 0 – 22 0 - 24 
     
Baseline FAST highest score  
    N 447 741 115 1303 
    Mean (SD) 10.2 (2.68) 10.4 (2.57) 9.8 (2.68) 10.2 (2.62) 
    Median 10.0 10.0 10.0 10.0 
    Range 4 - 16 4 – 16 4 – 16 4 - 16 
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Table 2: Crude incidence of mortality and CVAE in risperidone studies 
 Mortality  Any CVAE 
Study n/N % P-valuea  n/N % P-valuea 
All studies        
 Risperidone 40/1009 4.0 0.527  49/1009 4.9 <0.001 
 Placebo 22/712 3.1   11/712 1.5  
AUS-5        
 Risperidone 6/167 3.6 0.769  18/167 10.8 0.002 
 Placebo 5/170 2.9   4/170 2.4  
BEL-14        
 Risperidone 1/20 5.0 1.000  0/20 0 -- 
 Placebo 0/19 0   0/19 0  
INT-24        
 Risperidone 1/115 0.9 0.119  12/115 10.4 0.010 
 Placebo 5/114 4.4   2/114 1.8  
INT-83        
 Risperidone 0/10 0 0.444  1/10 10.0 1.000 
 Placebo 1/8 12.5   0/8 0  
USA-232        
 Risperidone 9/235 3.8 0.445  5/235 2.1 0.283 
 Placebo 6/238 2.5   2/238 0.8  
USA-63        
 Risperidone 23/462 5.0 0.383  13/462 2.8 0.773 
 Placebo 5/163 3.1   3/163 1.8  
a Cochran-Mantel-Haenszel test stratified by study for ‘All Studies’; Fisher’s exact test for individual 
studies. 
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Table 3A: Treatment-by-Factor Incidence of Any CVAE – Factors with Treatment-by-Factor Interaction P-value <0.05 (Cox Regression) 
 Present Not Present  
 
Risperidone Placebo 
RIS:PLA HR 
(95% CI) Risperidone Placebo 
RIS:PLA HR 
(95% CI) 
Interaction 
p-valuea 
 
Age ≥80 years 40/697 (5.7%) 11/466 (2.4%) 2.41 (1.24, 4.70) 9/312 (2.9%) 0/246 -- 0.032 
        
Cardiovascular Medical 
History 27/677 (4.0%) 9/472 (1.9%) 2.01 (0.95, 4.28) 10/196 (5.1%) 0/107 -- 0.036 
 
Delusions (diagnosis) 14/459 (3.1%) 7/347 (2.0%) 1.47 (0.59, 3.65) 35/530 (6.6%) 4/346 (1.2%) 5.88 (2.09, 16.53) 0.043 
 
Depressed Mood  (diagnosis) 4/112 (3.6%) 3/54 (5.6%) 0.54 (0.12, 2.40) 45/877 (5.1%) 8/639 (1.3%) 4.16 (1.96, 8.82) 0.025 
 
Creatinine Clearance 
decrease ≥20% (treatment-
emergent) 0/63 1/39 (2.6%) -- 36/794 (4.5%) 10/559 (1.8%) 2.49 (1.24, 5.02) 0.049 
 
Creatinine Clearance 
decrease ≥20% (treatment-
emergent with 7-day rule) 0/41 1/23 (4.4%) -- 36/816 (4.4%) 10/575 (1.7%) 2.49 (1.24, 5.02) 0.049 
 
Beta Blockers (treatment-
emergent) 9/124 (7.3%) 0/89 -- 40/885 (4.5%) 11/623 (1.8%) 2.54 (1.30, 4.95) 0.041 
a Likelihood ratio test of treatment-by-factor interaction term in Cox proportional hazards regression. 
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Table 3B: Treatment-by-Factor Incidence of Death – Factors with Treatment-by-Factor Interaction P-value <0.05 (Cox Regression) 
 Present Not Present  
 
Risperidone Placebo 
RIS:PLA HR 
(95% CI) Risperidone Placebo 
RIS:PLA HR 
(95% CI) 
Interaction 
p-value 
 
Depressed Mood (diagnosis) 0/112 5/54 (9.3%) -- 39/877 (4.4%) 17/639 (2.6%) 1.52 (0.86, 2.70) <0.001 
 
Anti-inflammatory 
medications (treatment-
emergent) 16/310 (5.2%) 3/213 (1.4%) 3.42 (1.00, 11.76) 24/699 (3.4%) 19/499 (3.8%) 0.78 (0.42, 1.43) 0.021 
 
Anti-inflammatory 
medications (treatment-
emergent with 7-day rule) 16/310 (5.2%) 3/211 (1.4%) 3.42 (1.00, 11.75) 24/699 (3.4%) 19/501 (3.8%) 0.78 (0.42, 1.43) 0.021 
a Likelihood ratio test of treatment-by-factor interaction term in Cox proportional hazards regression. 
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Figure 1: Incidence of Cerebrovascular Adverse Event and Mortality by Baseline Risk Factor – 
Placebo Subjects 
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Figure 2: Incidence of CVAE and Mortality by Treatment-emergent Risk Factor – Placebo Subjects 
 
 
 
 
 
